Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takara Holdings Inc.

Latest From Takara Holdings Inc.

Deal Watch: Gilead’s Immunology Collaboration With Verily Continues Pivot Away From Virology

Gilead’s tie-up with Google’s Verily will explore the immunological underpinnings of rheumatoid arthritis, lupus and GI disorders. Janssen acquires BeneVir and its oncolytic virus expertise, while United Therapeutics buys out SteadyMed.

Deals Commercial

Deal Watch Asia Focus: Pfenex Licenses Asian Rights To Forteo Copy To NT Pharma Group

Otsuka obtains Japanese rights to two cancer gene therapy candidates from Takara. GlaxoSmithKline extends its protein degradation collaboration with Kymera.

Commercial Business Strategies

The Regenerative Market Brings The Future Closer

A clear sign the regenerative medicine and therapy market is making considerable progress comes from the amount of investor funding pouring into the space, and although a lot of the technology is still spoken about in the future tense, a variety of new companies are bringing the future much closer. An additional hallmark of the market is the role device companies are finding for themselves in an industry primarily lead by pharmaceutical businesses.

Medical Device Regenerative Medicine

Combining Chemical Genetics and Cancer Immunotherapy

Two years ago, a team at Stanford described a new "chemical genetics" technique--a more precise way to use small molecules to perturb gene products and living systems. Now they have published more data on the system. And of acute interest to drug developers, they have linked the work to therapeutic applications in cancer immunotherapy, showing the ability to regulate secreted proteins such as IL-2 and TNF.

BioPharmaceutical Research and Development Strategies
See All

Company Information

  • Industry
  • Diversified
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Takara Shuzo Co. Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Takara Holdings Inc.
  • Senior Management
  • Toshio Kakimoto, Pres.
  • Contact Info
  • Takara Holdings Inc.
    Phone: (81) 75 241-5110
    20 Naginatahoko-cho, Shijo-dori Karasuma
    Kyoto, 600-8688